No driving to the clinic, no sitting in a waiting room reading magazines from 2019
If the patient cannot tolerate the 2.4mg dose, then decrease the dose to 1.7mg for 4 weeks
In particular, LEAP2 (liver-expressed antimicrobial peptide 2), an endogenous antagonist of the ghrelin receptor GHSR, has emerged as a potential target for mitigating the weight regain often observed after discontinuation of GLP-1-based therapies [22,23]
Expand therapeutic use By focusing on health optimization rather than disease treatment, microdosing opens up possibilities for a broader range of patients
Working with licensed providers ensures that your treatment is rooted in medical insight
Mentre tirzepatide combina GLP-1 e GIP (entrambi incretine intestinali che agiscono su vie parzialmente sovrapposte), CagriSema combina GLP-1 e amilina (che agiscono su sistemi biologici distinti)